


02-23-05

SPW 1632

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7

Application Number

09/986,234

Filing Date

October 22, 2001

First Named Inventor

M. Lazar

Art Unit

1632

Examiner Name

A. Falk

Attorney Docket Number

UPN-L2066AUSA

ENCLOSURES (Check all that apply)

- | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/
Incomplete Application
<input type="checkbox"/> Reply to Missing Parts
under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a
Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board
of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify
below):
19 Reference documents |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Remarks

Customer No. 00270
Express Mail No. ED227898199US

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

HOWSON AND HOWSON

Signature

Mary E. Bak

Printed name

Mary E. Bak

Date

February 22, 2005

Reg. No.

31,215

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:


Signature

Typed or printed name

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UPN-L2066AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 09/986,234

Confirmation No.: 4995

Applicant : M. Lazar

Filed : October 22, 2001

TC/A.U. : 1632

Examiner : A. Falk

Customer No. : 00270

Title : COMPOSITIONS, METHODS, AND KITS RELATING TO RESISTIN

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the documents are enclosed herewith.

Pursuant to 37 CFR 1.97(e)(1), each item of information number (i)-(viii) in this paper was first cited in a Supplementary European Search Report in the counterpart European patent application more than three months prior to the filing of this paper.

This Information Disclosure Statement is submitted more than three months from the filing date of this application but before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

Express Mail No. ED227898199US

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

REMARKS

Listed below are documents cited in the Supplemental European Search Report dated June 3, 2004 in the corresponding European Patent Application No. 00930170.6, filed November 23, 2001. A copy of the Report is enclosed.


- (i) International Patent Publication No. WO-00/05259, published February 3, 2000 (item AN)
- (ii) International Patent Publication No. WO-00/20447, published April 13, 2000 (item AO)
- (iii) International Patent Publication No. WO-98/58061, published December 23, 1998
- (iv) International Patent Publication No. WO-99/11293, published March 11, 1999
- (v) International Patent Publication No. WO-99/55868, published November 4, 1999 (item AQ)
- (vi) REGINATO et al., "Mechanisms by which Thiazolidinediones Enhance Insulin Action", *Trends Endo. Metab.* December 1999 10(1):9-13 (item AX)
- (vii) STEPPAN et al., "The hormone resistin links obesity to diabetes", *Nature* January 18, 2001 409(6818):307-312 (item BR)
- (viii) STEPPAN et al., "Resistin and obesity-associated insulin resistance", *Trends Endo. Metab.* January-February 2002 13(1):18-23 (item AZ)

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818



PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/986,234
				Filing Date	October 22, 2001
				First Named Inventor	M. Lazar
				Group Art Unit	1632
				Examiner Name	A. Falk
Sheet	1	of	3	Attorney Docket Number	UPN-L2066AUSA


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	2001-0011077	08-02-2001	Albone et al.	
	AB	2002-0111476	08-15-2002	Franz-Bacon et al.	
	AC	2003-0166906	09-04-2003	Moore et al.	
	AD	2004-0018980	01-29-2004	Gurney et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AL	WO-00/00610	01-06-2000	Lal et al.		
	AM	WO-00/04923	02-03-2000	Albone et al.		
	AN	WO-00/05259	02-03-2000	Albone et al.		
	AO	WO-00/20447	04-13-2000	Shimkets		
	AP	WO-99/31236	06-24-1999	Bougueleret et al.		
	AQ	WO-99/55868	11-04-1999	Gurney et al.		

Examiner Signature	Date Considered
--------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		<i>Application Number</i>	09/986,234		
		<i>Filing Date</i>	October 22, 2001		
		<i>First Named Inventor</i>	M. Lazar		
		<i>Group Art Unit</i>	1632		
		<i>Examiner Name</i>	A. Falk		
Sheet	2	of	3	<i>Attorney Docket Number</i>	UPN-L2066AUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR	FORMAN et al., "Unique response pathways are established by allosteric interactions among nuclear hormone receptors", <i>Cell</i> May 19, 1995 81(4):541-550	
	AS	FRIEDMANN, T., "Overcoming the obstacles to gene therapy", <i>Sci. Amer.</i> June 1997 276(6):96-101	
	AT	HOLCOMB et al., "FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family", <i>EMBO J.</i> August 1, 2000 19(15):4046-4055	
	AU	KLIEWER et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma", <i>Proc. Nat. Acad. Sci. USA</i> April 29, 1997 94(9):4318-4323	
	AV	MUKHERJEE et al., "Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists", <i>Nature</i> May 27, 1999 386(6623):407-410	
	AW	ORKIN et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy", December 7, 1995	
	AX	REGINATO et al., "Mechanisms by which Thiazolidinediones Enhance Insulin Action", <i>Trends Endo. Metab.</i> December 1999 10(1):9-13	
	AY	STEPPAN et al., "A family of tissue-specific resistin-like molecules", <i>Proc. Nat. Acad. Sci. USA</i> January 16, 2001 98(2):502-506	
	AZ	STEPPAN et al., "Resistin and obesity-associated insulin resistance", <i>Trends Endo. Metab.</i> January-February 2002 13(1):18-23	
	BR	STEPPAN et al., "The hormone resistin links obesity to diabetes", <i>Nature</i> January 18, 2001 409(6818):307-312	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		<i>Application Number</i>	09/986,234		
		<i>Filing Date</i>	October 22, 2001		
		<i>First Named Inventor</i>	M. Lazar		
		<i>Group Art Unit</i>	1632		
		<i>Examiner Name</i>	A. Falk		
Sheet	3	of	3	<i>Attorney Docket Number</i>	UPN-L2066AUSA

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BS	TONTONOZ et al., "Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor", <i>Cell</i> December 30, 1994 79(7):1147-1156	
	BT	VERMA et al., "Gene therapy -- promises, problems and prospects", <i>Nature</i> September 18, 1997 389(6648):239-242	
	BU	WALL, R.J., "Transgenic livestock: Progress and prospects for the future", <i>Theriogenology</i> January 1, 1996 45(1):57-68	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.